Edition:
United Kingdom

Organovo Holdings Inc (ONVO.OQ)

ONVO.OQ on NASDAQ Stock Exchange Global Market

1.12USD
23 Apr 2018
Change (% chg)

$-0.05 (-4.66%)
Prev Close
$1.18
Open
$1.19
Day's High
$1.19
Day's Low
$1.10
Volume
104,141
Avg. Vol
235,180
52-wk High
$3.19
52-wk Low
$0.91

Chart for

About

Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products,... (more)

Overall

Beta: 3.21
Market Cap(Mil.): $215.48
Shares Outstanding(Mil.): 105.63
Dividend: --
Yield (%): --

Financials

  ONVO.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -0.39 -- --
ROI: -69.96 1.58 14.38
ROE: -70.97 2.41 16.07

BRIEF-Organovo Division Samsara Sciences Announces Multi-Year Supply Agreement

* ORGANOVO DIVISION SAMSARA SCIENCES ANNOUNCES MULTI-YEAR SUPPLY AGREEMENT WITH LONZA BIOSCIENCE SOLUTIONS

26 Mar 2018

BRIEF-Organovo Holdings Files For Mixed Shelf Offering Of Up To $100 Mln

* ORGANOVO HOLDINGS INC FILES FOR MIXED SHELF OFFERING OF UP TO $100 MILLION - SEC FILING Source text (http://bit.ly/2EQ7FuR) Further company coverage:

08 Feb 2018

BRIEF-Organovo Reports Q3 Loss Per Share Of $0.07

* ORGANOVO ANNOUNCES FISCAL THIRD-QUARTER 2018 RESULTS; COMPANY UPDATES FULL-YEAR FISCAL 2018 OUTLOOK

08 Feb 2018

BRIEF-Organovo Receives Orphan Designation From U.S. FDA For 3D Bioprinted Therapeutic Liver Tissue

* ORGANOVO RECEIVES ORPHAN DESIGNATION FROM U.S. FDA FOR 3D BIOPRINTED THERAPEUTIC LIVER TISSUE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY Source text for Eikon: Further company coverage:

26 Dec 2017

BRIEF-Organovo posts Q3 loss per share $0.09

* Organovo announces fiscal second-quarter 2018 results; company shifts commercial focus to higher-value disease modeling opportunities and updates full-year fiscal 2018 outlook

09 Nov 2017

BRIEF-Organovo and Viscient Biosciences collaborate to develop custom research platform for studying liver disease

* Organovo and Viscient Biosciences collaborate to develop custom research platform for studying liver disease

06 Nov 2017

Earnings vs. Estimates